Annual report pursuant to Section 13 and 15(d)

Acquisitions, Investments, and Licenses - Acquisition Narrative (Details)

v3.3.1.900
Acquisitions, Investments, and Licenses - Acquisition Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 5 Months Ended 8 Months Ended 12 Months Ended
Aug. 31, 2015
May. 31, 2015
May. 31, 2014
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2015
Dec. 31, 2015
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Business Acquisition [Line Items]                                
Revenues       $ 276,191 $ 143,034 $ 42,429 $ 30,084 $ 25,533 $ 19,773 $ 23,545 $ 22,274     $ 491,738 $ 91,125 $ 96,530
Net income (loss)                           (30,028) (171,666) (114,407)
In-process research and development                           0 $ 12,055 $ 0
Common Stock                                
Business Acquisition [Line Items]                                
Stock price $ 12.38 $ 13.88                            
Bio-Reference Laboratories, Inc.                                
Business Acquisition [Line Items]                                
Value of equity interest issued or issuable $ 2,259                              
Measurement period adjustment, accounts receivable       5,200                        
Measurement period adjustment, inventory       (200)                        
Measurement period adjustment, other current assets       7,000                        
Measurement period adjustment, property, plant and equipment       6,200                        
Measurement period adjustment, Intangible assets       (6,900)                        
Measurement period adjustment, goodwill       (31,600)                        
Measurement period adjustment, other assets (long-term)       1,100                        
Measurement period adjustment, accounts payable       (1,500)                        
Measurement period adjustment, accrued expenses       1,600                        
Measurement period adjustment, income taxes payable       (20,000)                        
Measurement period adjustment, deferred tax liability       500                        
Revenues                       $ 321,900        
Net income (loss)                       $ 3,200        
Total purchase price $ 950,148                              
Bio-Reference Laboratories, Inc. | Common Stock                                
Business Acquisition [Line Items]                                
Common stock received, in shares 76,566,147                              
Acquired entity share price $ 34.05                              
EirGen Pharma Limited                                
Business Acquisition [Line Items]                                
Total purchase price   $ 100,200                            
Value of equity interest issued or issuable   33,600                            
Measurement period adjustment, goodwill       16,600                        
Measurement period adjustment, deferred tax liability       2,500                        
Revenues                         $ 13,500      
Measurement period adjustment, in-process research and development assets       $ 19,000                        
Net income (loss)                         $ 1,400      
Acquisition related costs                           $ 500    
Total purchase price   $ 133,800                            
EirGen Pharma Limited | Common Stock                                
Business Acquisition [Line Items]                                
Common stock received, in shares   2,420,487                            
Inspiro                                
Business Acquisition [Line Items]                                
Common stock received, in shares     999,556                          
Total purchase price     $ 1,500                          
Stock price       $ 8.57               $ 8.57 $ 8.57 $ 8.57    
Value of equity interest issued or issuable     $ 8,600                          
Voting percent     100.00%                          
In-process research and development     $ 10,100                          
Selling, General and Administrative Expenses | Bio-Reference Laboratories, Inc.                                
Business Acquisition [Line Items]                                
Acquisition related costs                           $ 6,200    
Trade names | Bio-Reference Laboratories, Inc.                                
Business Acquisition [Line Items]                                
Useful life                           5 years    
Internally Developed Software | Bio-Reference Laboratories, Inc.                                
Business Acquisition [Line Items]                                
Useful life                           3 years    
Minimum | Trade names                                
Business Acquisition [Line Items]                                
Useful life                           4 years    
Minimum | Customer relationships                                
Business Acquisition [Line Items]                                
Useful life                           6 years    
Minimum | Customer relationships | Bio-Reference Laboratories, Inc.                                
Business Acquisition [Line Items]                                
Useful life                           10 years    
Minimum | Technology | Bio-Reference Laboratories, Inc.                                
Business Acquisition [Line Items]                                
Useful life                           8 years    
Minimum | IPR&D assets | EirGen Pharma Limited                                
Business Acquisition [Line Items]                                
Useful life                           3 years    
Maximum | Trade names                                
Business Acquisition [Line Items]                                
Useful life                           5 years    
Maximum | Customer relationships                                
Business Acquisition [Line Items]                                
Useful life                           20 years    
Maximum | Customer relationships | Bio-Reference Laboratories, Inc.                                
Business Acquisition [Line Items]                                
Useful life                           20 years    
Maximum | Technology | Bio-Reference Laboratories, Inc.                                
Business Acquisition [Line Items]                                
Useful life                           12 years    
Maximum | IPR&D assets | EirGen Pharma Limited                                
Business Acquisition [Line Items]                                
Useful life                           20 years